Join episode host, Todd Eury, founder and CEO of the Pharmacy Podcast Network, as he discusses the indispensable role of pharmacists in T2D care with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP and Rohit Moghe, PharmD, MSPH, CDCES. These pharmacist experts will share insights on why the role of pharmacists is so important in T2D care, including reviewing data on how pharmacist involvement improves measurable outcomes for patients with T2D. To raise awareness, they will also review T2D treatment recommendations from major medical societies.This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.Faculty Presenters:Todd Eury, BSCEOPharmacy Podcast Network Brownsville, PennsylvaniaDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCPEndocrine Clinical Pharmacist and Director of Education and Training in Diabetes TechnologyThe Cleveland Clinic Cleveland, OhioRohit Moghe, PharmD, MSPH, CDCESAmbulatory Care & Population Health Clinical PharmacistTrinity Health Mid-Atlantic Langhorne, Pennsylvania
What are the prevalence, increased risk, and impact of cardiovascular disease (CVD) among patients with type 2 diabetes (T2D)? Join experts: Dr John Anderson (primary care physician), Dr Pam Taub (cardiologist), and Dr Mark Greathouse (cardiologist) as they review the relationship between T2D and CVD, including how T2D exacerbates CVD and the risk from CVD, and what the national medical associations recommend for patients with T2D and CVD.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseePam Taub, MD, FACCCardiologist and Professor of MedicineDirector, Cardiac Rehabilitation and Wellness CenterUC San Diego HealthSan Diego, CaliforniaMark Greathouse, MDSenior Clinical CardiologistSt. Clair HealthPittsburg, Pennsylvania
What is the impact of insufficient GLP-1 activity in type 2 diabetes (T2D)? Join experts in T2D: Dr John Anderson, Dr Javier Morales, and Dr Richard Pratley as they review the role of GLP-1 in glucose regulation, consider the impact of insufficient GLP-1 activity on pancreatic beta cells in patients with T2D, and discuss possibilities to overcome insufficient GLP-1 activity in patients with T2D.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeJavier Morales, MD, FACP, FACEInternal Medicine, Diabetes, and Primary CareAssociate Clinical ProfessorHofstra/Northwell School of Medicine at the Donald and Barbara Zucker School of MedicineLong Island, New YorkRichard E. Pratley, MDInternal Medicine and DiabetesAdventHealth Diabetes InstituteOrlando, Florida
What is the role of endogenous GLP-1 in the pathophysiology of T2D? Join multidisciplinary experts in T2D: Dr John Anderson, Dr Vivian Fonseca, and Dr Jim Gavin as they discuss the fascinating history of GLP-1 discovery and the role of endogenous GLP-1 in the pathophysiology of T2D.This podcast is sponsored by Novo Nordisk and is intended for Healthcare Practitioners.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeJames R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaVivian A. Fonseca, MD, FRCPProfessor of Medicine, Assistant Dean for ResearchTulane UniversityNew Orleans, Louisiana
What do you know about the role of beta-cell dysfunction in the pathophysiology of type 2 diabetes (T2D)? Join primary care experts in T2D: Dr. John Anderson, Dr. Stephen Brunton and Dr. James LaSalle as we discuss the beta-cell function and its critical role in T2D pathogenesis, what clinicians know or should know about it and how it is measured in the clinic, and how our current knowledge of beta-cell function in T2D may affect future research on T2D treatment.This podcast is sponsored by Novo Nordisk and is intended for clinicians. The opinions expressed are those of the speakers and not Novo Nordisk.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeStephen Brunton, MD, FAAFPExecutive DirectorPrimary Care Metabolic GroupWinnsboro, South CarolinaJames LaSalle, DO, FAAFPMedical Arts of Excelsior Springs, Inc.Excelsior Springs, Missouri
What is the burden of the type 2 diabetes (T2D) epidemic? Join experts in T2D: Dr. John Anderson (primary care provider), Dr. Susan Cornell (clinical pharmacist and certified diabetes care and education specialist) and Dr. Doron Schneider (primary care provider) as they discuss the enormous physical, emotional, psychological and economic burden of T2D and its comorbidities on the US healthcare system and on their patients and what they, as clinicians need to do to ease this burden.This podcast is sponsored by Novo Nordisk and is intended for clinicians.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeSusan Cornell, BS, PharmD, CDCES, FAPhA, FADCESAssociate Director of Experiential EducationProfessor of Pharmacy PracticeMidwestern University Chicago College of PharmacyDowners Grove, IllinoisDoron Schneider, MD, MBA, FACPVice President, Population Health ServicesTandigm HealthWest Conshohocken, Pennsylvania
What is the impact of COVID-19 on adult patients with type 2 diabetes (T2D) and how do we navigate healthcare when an epidemic and pandemic seemingly join forces to further exacerbate patient outcomes? Join experts in T2D: Dr. John Anderson (primary care provider), Dr. Eden Miller (primary care provider), and Dr. Serge Jabbour (endocrinologist) for an in-depth discussion on how COVID-19 impacts patients with T2D and what you can do to help your patients as new information is discovered during this evolving landscape.This podcast is sponsored by Novo Nordisk and is intended for clinicians. The opinions expressed are those of the speakers and not Novo Nordisk.Faculty Presenters:John E. Anderson, MDInternal Medicine and DiabetesThe Frist ClinicNashville, TennesseeEden Miller, DO, FOMADiabetes Care, Obesity, Family MedicineFounder, Diabetes and Obesity Care, LLCBend, OregonSerge A. Jabbour, MD, FACP, FACEDiabetes, Clinical Trials of Diabetes Treatments, ObesityProfessor of Medicine, Division of Endocrinology, Diabetes, and Metabolic DiseasesDirector, Jefferson Diabetes Center, Division of Endocrinology, Diabetes and Metabolic DiseasesSidney Kimmel Medical College/ Thomas Jefferson UniversityPhiladelphia, PA